With 59216.0 shares changed hands, the volume of the stock remained heavier than its average volume of 34560.0 shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $10.6747 whereas the lowest price it dropped to was $8.91. The 52-week range on SNSE shows that it touched its highest point at $18.35 and its lowest point at $5.00 during that stretch. It currently has a 1-year price target of $30.00. Beta for the stock currently stands at 0.31.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SNSE was up-trending over the past week, with a rise of 24.97%, but this was up by 21.66% over a month. Three-month performance surged to 26.92% while six-month performance rose 49.96%. The stock gained 7.73% in the past year, while it has lost -2.44% so far this year. A look at the trailing 12-month EPS for SNSE yields -21.31 with Next year EPS estimates of -15.05. For the next quarter, that number is -4.81. This implies an EPS growth rate of 24.29% for this year and 17.17% for next year. EPS is expected to grow by 19.69% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -11.38%.
Float and Shares Shorts:
At present, 1.26 million SNSE shares are outstanding with a float of 0.83 million shares on hand for trading. On 2025-11-14, short shares totaled 5342.0, which was 42.0 higher than short shares on 1760486400. In addition to Dr. Edward Van der Horst Ph.D. as the firm’s Chief Scientific Officer, Ms. Stephanie Krebs M.B.A., M.S. serves as its Chief Business Officer.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-09-30, SNSE reported revenue of $0.0 and operating income of -$4851000.0. The EBITDA in the recently reported quarter was -$4528000.0 and diluted EPS was -$3.62.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SNSE since 3 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$22.86496 being high and -$23.66724 being low. For SNSE, this leads to a yearly average estimate of -$23.46667. The surprise factor in the prior quarter was -$5.
